Respiratory Failure Clinical Trial
— CLOUDHFOTOfficial title:
Closed-Loop O2 Use During High Flow Oxygen Treatment Of Critical Care Adult Patients (CLOUDHFOT)- a Randomized Cross-over Study
Verified date | April 2024 |
Source | Basaksehir Çam & Sakura City Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
High flow nasal oxygen therapy (HFNO) is an established modality in the supportive treatment of patients suffering from acute hypoxemic respiratory failure. The high humidified gas flow supports patient's work of breathing, reduces dead space ventilation, and improves functional residual capacity while using an unobtrusive patient's face interface [Mauri et al, 2017; Möller et al, 2017]. As hyperoxia is considered not desirable [Barbateskovic et al, 2019] during any oxygen therapy, the inspired O2 concentration is usually adapted to a pre-set SpO2 target-range of 92-96% in patients without hypercapnia risk, and of 88-92% if a risk of hypercapnia is present [O'Driscoll et al, 2017; Beasley et al, 2015]. In most institutions, the standard of care is to manually adapt the FiO2, although patients frequently have a SpO2 value outside the target range. A new closed loop oxygen controller designed for HFNO was recently developed (Hamilton Medical, Bonaduz, Switzerland). The clinician sets SpO2 targets, and the software option adjusts FiO2 to keep SpO2 within the target ranges. The software option offers some alarms on low and high SpO2 and high FiO2. Given the capability, on the one hand, to quickly increase FiO2 in patients developing sudden and profound hypoxia, and, on the other hand, of automatically preventing hyperoxia in patients improving their oxygenation, such a system could be particularly useful in patients treated with HFNO. A short-term (4 hours vs 4 hours) crossover study indicated that this technique improves the time spent within SpO2 pre-defined target for ICU patients receiving high-flow nasal oxygen therapy [Roca et al, 2022]. Due to its simplicity, HFNO is increasingly used outside the ICU during transport and in the Emergency Room (ER). This environment poses specific challenges, as patients may deteriorate very quickly and depending on patient's flow, healthcare providers can easily be overwhelmed. We thus propose to evaluate closed loop controlled HFNO in ER patients. The hypothesis of the study is that closed loop oxygen control increases the time spent within clinically targeted SpO2 ranges and decreases the time spent outside clinical target SpO2 ranges as compared to manual oxygen control in ER patients treated with HFNO.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | December 30, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient admitted to the ER - Requiring NHFO - Requiring FiO2 = 30% to keep SpO2 in the target ranges defined by the clinician - Aged over 18 years - Written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation - In case that the consent is given by the relative, patient consent will be requested as soon as the patient will be able to provide informed written consent Exclusion Criteria: Patients who fulfil any of the following exclusion criteria are not eligible for study participation: - Patient with indication for immediate CPAP, NIV, or invasive mechanical ventilation - Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine > 1 mg/h - Low quality on the SpO2 measurement using finger and ear sensor (quality index below 60% on the Massimo SpO2 sensor, which is displayed by a red or orange color bar) - Severe acidosis (pH = 7.30) - Pregnant woman - Patients deemed at high risk for need of mechanical ventilation within the next 12 hours - Chronic or acute dyshemoglobinemia: methemoglobin, CO poisoning, sickle cell disease - Tracheotomized patient - Formalized ethical decision to withhold or withdraw life support - Patient under guardianship - Patient deprived of liberties - Patient included in another interventional research study under consent - Patient already enrolled in the present study in a previous episode of acute respiratory failure Post enrollment exclusion criteria - Apparition of a persistent low quality SpO2 signal - Need for an emergent intubation - Discharge from ER |
Country | Name | City | State |
---|---|---|---|
Turkey | Dr.Suat Seren Chest Diseasees Hospital | Izmir |
Lead Sponsor | Collaborator |
---|---|
Basaksehir Çam & Sakura City Hospital | Hamilton Medical AG |
Turkey,
Dijkman KP, Goos TG, Dieleman JP, Mohns T, van Pul C, Andriessen P, Kroon AA, Reiss IK, Niemarkt HJ. Predictive Intelligent Control of Oxygenation in Preterm Infants: A Two-Center Feasibility Study. Neonatology. 2023;120(2):235-241. doi: 10.1159/000527539. Epub 2022 Dec 8. — View Citation
O'Driscoll BR, Kirton L, Weatherall M, Bakerly ND, Turkington P, Cook J, Beasley R. Effect of a lower target oxygen saturation range on the risk of hypoxaemia and elevated NEWS2 scores at a university hospital: a retrospective study. BMJ Open Respir Res. 2024 Feb 29;11(1):e002019. doi: 10.1136/bmjresp-2023-002019. — View Citation
Roca O, Caritg O, Santafe M, Ramos FJ, Pacheco A, Garcia-de-Acilu M, Ferrer R, Schultz MJ, Ricard JD. Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study). Crit Care. 2022 Apr 14;26(1):108. doi: 10.1186/s13054-022-03970-w. — View Citation
Sandal O, Ceylan G, Topal S, Hepduman P, Colak M, Novotni D, Soydan E, Karaarslan U, Atakul G, Schultz MJ, Agin H. Closed-loop oxygen control improves oxygenation in pediatric patients under high-flow nasal oxygen-A randomized crossover study. Front Med (Lausanne). 2022 Nov 16;9:1046902. doi: 10.3389/fmed.2022.1046902. eCollection 2022. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of time spent in optimal SpO2 range | The optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician. | 6 hours | |
Secondary | Percentage of time with SpO2 signal available | Time with SpO2 signal available | 6 hours | |
Secondary | Percentage of time with SpO2 below target range | SpO2 values below the optimal range | 6 hours | |
Secondary | Percentage of time with SpO2 above target range | SpO2 values above the optimal range | 6 hours | |
Secondary | Percentage of time with SpO2 outside optimal range | SpO2 values outside the optimal range | 6 hours | |
Secondary | Percentage of time with with FiO2 below 40% | Duration of time with FiO2 < 40 % | 6 hours | |
Secondary | Percentage of time with with FiO2 above 60% | Duration of time with FiO2 > 60 % | 6 hours | |
Secondary | Percentage of time with with FiO2 = 100% | Duration of time with FiO2 = 60 % | 6 hours | |
Secondary | Mean SpO2/FiO2 | Mean SpO2/FiO2 | 6 hours | |
Secondary | Number of events with SpO2 below of target range (duration >10 s) | Frequency of events with SpO2 below of target range (duration >10 s) | 6 hours | |
Secondary | Number of events with SpO2 below of target range (duration >60 s) | Frequency of events with SpO2 below of target range (duration >60 s) | 6 hours | |
Secondary | Number of events with SpO2 below the predefined low SpO2 emergency limit | Frequency of events with SpO2 below of the predefined low SpO2 emergency limit | 6 hours | |
Secondary | Number of events with SpO2 above the predefined low SpO2 emergency limit | Frequency of events with SpO2 above of the predefined low SpO2 emergency limit | 6 hours | |
Secondary | Total oxygen use | Amount of additional oxygen use | 6 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Recruiting |
NCT03662438 -
HOPE (Home-based Oxygen [Portable] and Exercise) for Patients on Long Term Oxygen Therapy (LTOT)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04030208 -
Evaluating Safety and Efficacy of Umbulizer in Patients Requiring Intermittent Positive Pressure Ventilation
|
N/A | |
Recruiting |
NCT04668313 -
COVID-19 Advanced Respiratory Physiology (CARP) Study
|
||
Recruiting |
NCT04542096 -
Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
|
||
Recruiting |
NCT05883137 -
High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
|
||
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT03943914 -
Early Non-invasive Ventilation and High-flow Nasal Oxygen Therapy for Preventing Delayed Respiratory Failure in Hypoxemic Blunt Chest Trauma Patients.
|
N/A | |
Active, not recruiting |
NCT03472768 -
The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support
|
||
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Not yet recruiting |
NCT02542423 -
Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.
|
N/A | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01885442 -
TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01659268 -
Performance of Baccalaureate Nursing Students in Insertion of Laryngeal Mask: a Trial in Mannequins
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01204281 -
Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
|
Phase 4 | |
Terminated |
NCT01333059 -
Cycling of Sedative Infusions in Critically Ill Pediatric Patients
|
N/A |